|Videos|July 16, 2014
Conclusion: Addressing Unmet Needs in Lung Cancer
Advertisement
Episodes in this series
For High-Definition, Click
In the final segment of the discussion, panelists provide their finals on thoughts on emerging areas in the treatment of lung cancer.
View the video, to hear each experts insight!
Advertisement
Related to this article
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Yale experts address borderline resectability, perioperative chemoimmunotherapy, pCR-guided adjuvant therapy, and osimertinib in early-stage NSCLC.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
Phase 3 SAFFRON data support EU and Japanese filings for savolitinib plus osimertinib in EGFR-mutated NSCLC with MET overexpression or amplification.
RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
IBI363 plus bevacizumab extended progression-free survival vs docetaxel in patients with immunotherapy-resistant lung adenocarcinoma in a randomized phase 1b study.
Advertisement
Advertisement
Trending on OncLive
1
DLL3-Targeted Therapy and KRAS Inhibition Lead Lung Cancer Data Highlights From ESMO 2026
2
Dr Garrido-Laguna on the Efficacy and Safety of QTX3034-Based Combinations in KRAS G12D–Mutated CRC
3
Rocbrutinib Plus R-CHOP Elicits Responses in Previously Untreated B-Cell Lymphomas
4
Lirafugratinib Added to NCCN Guidelines for Previously Treated FGFR2-Rearranged CCA
5